Fig. 1 · Structure

Documents & Downloads

Azelastine HCl (Allergodil)

Cat. No. A10117 CAS 79307-93-0
Azelastine is a potent, second-generation, selective, histamine antagonist (histamine-H1-receptor antagonist).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Azelastine hydrochloride displaced an H1-receptor radioligand in intact human U373 MG cells. Binding remained detectable after histamine-induced receptor internalization, with no significant change in the reported pIC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Histamine receptor

Azelastine HCl (Allergodil) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Azelastine HCl (Allergodil) from 2 published references. In vitro models include primary mouse dorsal root ganglion sensory neurons.

Azelastine HCl (Allergodil) In Vitro Studies

In cultured mouse sensory neurons, azelastine hydrochloride reduced depolarization-evoked calcium-associated fluorescence. The significant reported comparison was 100 µM versus control; this assay does not establish a selective channel target. [2]

H1 radioligand displacement in intact U373 MG cells

Biochemical assay · Intact human U373 MG astrocytoma cells, with or without histamine pretreatment [1]

Azelastine displaced [3H]mepyramine with a one-site fit. Histamine pretreatment did not significantly change its binding parameters. This assay measures receptor binding; it does not directly measure clinical sedation or functional antagonism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of 5 nM [3H]mepyramine in cells without histamine pretreatmentpIC50 7.27 ± 0.07 (mean ± S.E.M.; n=4)[1]
Displacement of 5 nM [3H]mepyramine after histamine pretreatmentpIC50 7.08 ± 0.06 (mean ± S.E.M.; n=4); no significant change versus control[1]

Literature-Reported Treatment Conditions

Treatment concentration
Various azelastine concentrations in a displacement series; radioligand 5 nM [3H]mepyramine.
Exposure duration
120 min binding incubation at 4°C; comparison cells pretreated with 0.1 mM histamine for 30 min at 37°C and washed.
Method
Intact-cell competitive radioligand binding in normal HEPES buffer.
Reported limits
Individual azelastine concentrations are plotted, not tabulated. Drug stock solvent is not specified in the shared methods; normal HEPES is the assay medium.
Methods and source locations

Compound reported in the paper: Azelastine hydrochloride; Compound label in the paper: Azelastine

Evidence for the reported hydrochloride material; stereochemical composition was not specified. No validation of an Adooq lot or equivalence of formulations is implied.

pp. 67–70 Materials and Methods and Results; Table 1 (p. 71), azelastine row; Fig. 3d (p. 72); Figs. 1–2 shared controls

Displacement of 5 nM [3H]mepyramine in cells without histamine pretreatment: Intact-cell radioligand competition; pIC50 = −log[IC50 (M)]; quadruplicate determinations. — Table 1 (p. 71), azelastine/control row; pp. 68 Data analyses; Fig. 3d/caption (p. 72)

Displacement of 5 nM [3H]mepyramine after histamine pretreatment: One-site fitting of competition curves; shared data analysis uses Student’s t test with P<0.05 threshold. — Table 1 (p. 71), azelastine/histamine-pretreated row; p. 70 Results; Fig. 3d/caption (p. 72)

Depolarization-evoked calcium signal in mouse sensory neurons

Cell-based study · Primary mouse dorsal root ganglion sensory neurons [2]

Azelastine reduced the calcium-associated fluorescence response to high extracellular potassium. The reported significant post hoc comparison was 100 µM versus control; the experiment does not identify a selective ion-channel target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
High-K+-evoked increase in intracellular calcium-associated fluorescenceRelative Fluo-3 fluorescence Concentration-dependent reduction at 30 and 100 µM; 100 µM versus control P<0.05 (Dunn’s test at the 54-s peak); n=24–38[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 and 100 µM azelastine; stimulus 30 mM KCl.
Exposure duration
30 min pretreatment before KCl stimulation.
Method
Drug added to cultured sensory-neuron medium; calcium-associated fluorescence recorded by confocal microscopy.
Reported limits
In vitro drug solvent and a matched solvent control are not specified. Caption reports n=24–38 without identifying the sampling unit or donor count; biological independence is unclear. No viability or channel-selectivity control is reported in the read experiment.
Methods and source locations

Compound reported in the paper: Azelastine hydrochloride; Compound label in the paper: Azelastine

Evidence for the reported hydrochloride material; stereochemical composition was not specified. No validation of an Adooq lot or equivalence of formulations is implied.

p. 263 material identity; p. 264 sensory-neuron methods/results; p. 265 Fig. 3/caption; p. 266 discussion

High-K+-evoked increase in intracellular calcium-associated fluorescence: Fluo-3/confocal fluorescence after 30 mM KCl; Kruskal–Wallis test followed by Dunn’s test. No exact curve amplitudes extracted. — Fig. 3/caption (p. 265); neuronal methods and Results (p. 264)

Azelastine HCl (Allergodil) In Vivo Studies

Oral azelastine hydrochloride reduced scratching in an allergic mouse model. Terfenadine and dexamethasone were ineffective under the tested conditions. H1 blockade alone was not established as the explanation, and central suppression remains a possible contributor. [2]

Scratching response in an allergic mouse model

Animal study · Male ICR mice sensitized to mosquito salivary gland extract; scratching after extract challenge [2]

Oral azelastine reduced challenge-induced scratching, whereas terfenadine and dexamethasone did not under their tested conditions. The study does not establish that H1 blockade alone mediates the reduction; central suppression remains a potential contributor.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Scratching bouts after extract challengeScratch bouts/h Dose-dependent inhibition at 3–30 mg/kg; significant at 30 mg/kg versus vehicle (P<0.05, Dunnett’s test); means ± S.E.M., n=8 animals[2]

Conditions shared by the study groups

Route
Oral (peroral)
Frequency
Single pretreatment
Vehicle
0.5% carboxymethyl cellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Azelastine dose response
3, 10 and 30 mg/kg
Sensitized, challenged vehicle groupDose-dependent inhibition; 30 mg/kg significant versus vehicle, P<0.05. Lower doses have no significance marker in Fig. 1E.[2]
Terfenadine comparator
30 mg/kg
Sensitized, challenged vehicle groupNo effect on scratching reported under these conditions.[2]
Dexamethasone comparator
3 and 10 mg/kg
Sensitized, challenged vehicle groupNo effect on scratching reported under these conditions.[2]
Azelastine dose response
Model: Sensitized male ICR mice; 5 weeks old at the start of experiments
Treatment course: 30 min before challenge
Terfenadine comparator
Model: Sensitized male ICR mice; 5 weeks old at the start of experiments
Treatment course: 30 min before challenge
Dexamethasone comparator
Model: Sensitized male ICR mice; 5 weeks old at the start of experiments
Treatment course: 60 min before challenge
Methods and source locations

Compound reported in the paper: Azelastine hydrochloride; Compound label in the paper: AZL

Evidence for the reported hydrochloride material; stereochemical composition was not specified. No validation of an Adooq lot or equivalence of formulations is implied.

p. 263 drug/animal methods; p. 264 scratching results and Fig. 1A–E/caption; pp. 265–266 discussion

Scratching bouts after extract challenge: Videotaped behavior scored as bouts; several rapid scratches over about 1 s counted as one bout. Observation over 60 min; no exact bar heights extracted. — Fig. 1C–E/caption and Results (p. 264)

Azelastine dose response · p. 263 drug/animal methods; p. 264 scratching results and Fig. 1A–E/caption; pp. 265–266 discussion

Terfenadine comparator · p. 263 drug/animal methods; p. 264 scratching results and Fig. 1A–E/caption; pp. 265–266 discussion

Dexamethasone comparator · p. 263 drug/animal methods; p. 264 scratching results and Fig. 1A–E/caption; pp. 265–266 discussion

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 79307-93-0
Formula C22H24ClN3O.HCl
Molecular Weight 418.4
Synonyms Rhinolast; Astelin; Optilas; Optivar; Allergodil
SMILES
CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 27 mg/mL (64.53 mM)
Water 78 mg/mL (186.42 mM)
Ethanol 78 mg/mL (186.42 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Azelastine HCl (Allergodil) Research References

  1. [1] Shigeru Hishinuma, Yuko Sato, Yusuke Kobayashi, et al. Intact Cell Binding for In Vitro Prediction of Sedative and Non-sedative Histamine H1–Receptor Antagonists Based on Receptor Internalization Journal of Pharmacological Sciences (2008). PMID: 18446005 DOI: 10.1254/jphs.FP0071865 Source material
  2. [2] Eiji Ohtsuka, Sanae Kawai, Hiroshi Nojima, et al. Inhibitory Effect of Azelastine on Allergic Itch-Associated Response in Mice Sensitized With Mosquito Salivary Glands Extract Journal of Pharmacological Sciences (2003). PMID: 12686751 DOI: 10.1254/jphs.91.263 Source material

Added to your cart

View Cart Checkout
Loading...